Daniel E Afar
Inventor
Stats
- 27 US patents issued
- 36 US Applications filed
- most recent filing
This is official USPTO record data
Details
- 27 US Patents Issued
- 36 US Applications Filed
- 300 Total Citation Count
- May 17, 2017 Most Recent Filing
- Jun 1, 1999 Earliest Filing
Work History
| Patent Owner | Applications Filed | Year |
|---|---|---|
| AGENSYS, INC. | 6
1 4 5 1 3 4 2 2 2 2 3 | 1999
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 |
| UROGENESYS | 2
1 | 2008
2010 |
| Genentech, Inc. | 2
1 | 2004
2011 |
| ABBVIE BIOTHERAPEUTICS INC. | 1
| 2017
|
| ABBVIE INC. | 1
| 2017
|
Inventor Addresses
| Address | Duration |
|---|---|
| Brisbane, CA | May 15, 07 - May 15, 07 |
| Fremont, CA | Dec 07, 06 - Jul 24, 08 |
| Fremont, CA, US | Apr 16, 09 - Aug 23, 11 |
| LOS ALTOS HILLS, CA, US | Dec 07, 17 - Dec 07, 17 |
| Pacific Palisades, CA | Aug 21, 01 - Oct 07, 08 |
| Pacific Palisades, CA, US | Mar 20, 03 - Apr 09, 13 |
Technology Profile
| Technology | Matters | |
|---|---|---|
| A01K: | ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS | 1 |
| A01N: | PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF | 1 |
| A61K: | PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES | 21 |
Patents / Publication
| Patents / Publication # | Year of Publication / Issued | Title | Citations |
|---|---|---|---|
| 2017/0348,429 | 2017 | ANTI-cMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | 5 |
| 8414898 | 2013 | Serpentine transmembrane antigens expressed in human cancers and uses thereof | 33 |
| 8383777 | 2013 | 13-transmembrane protein expressed in prostate cancer | 1 |
| 2011/0318,371 | 2011 | Novel serpentine transmembrane antigens expressed in human cancers and uses thereof | 6 |
| 8053551 | 2011 | Serpentine transmembrane antigens expressed in human cancers and uses therefor | 6 |
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level.
>
Upgrade to our Level for up to -1 portfolios!.